Hob Biotech: MM09 sublingual spray Phase III clinical trial completes enrollment of the first batch of subjects
I'm PortAI, I can summarize articles.
Hob Biotech has signed an exclusive strategic cooperation agreement with Inmunotek to introduce the Oraltek® series of desensitization drugs into the Chinese market. The company's wholly-owned subsidiary, Shanghai Hob Biotech, has successfully completed the enrollment of the first batch of subjects for the Phase III clinical trial of the MM09 sublingual spray. In addition, three desensitization drugs have obtained clinical urgent import approval in the Guangdong-Hong Kong-Macao Greater Bay Area
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments